Creekmur Asset Management’s Gain Therapeutics GANX Stock Holding History

Creekmur Asset Management’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$7.86K	Hold	4,440	–	–	﹤0.01%	538
2025 Q2	$7.99K	Hold	4,440	–	–	﹤0.01%	546
2025 Q1	$8.48K	Hold	4,440	–	–	﹤0.01%	506
2024 Q4	$9.59K	Hold	4,440	–	–	﹤0.01%	429
2024 Q3	$7.9K	Hold	4,440	–	–	﹤0.01%	481
2024 Q2	$5.68K	Hold	4,440	–	–	﹤0.01%	573
2024 Q1	$16.7K	Hold	4,440	–	–	0.01%	403
2023 Q4	$14.5K	Buy	+4,440	New	+$12.3K	﹤0.01%	472

Other funds holding GANX

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

DCM

DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Creekmur Asset Management's GANX Position: Q3 2025 in Review

Creekmur Asset Management held its Gain Therapeutics (GANX) position steady in Q3 2025 at 4,440 shares worth $7.86K. The position accounts for ﹤0.01% of the portfolio, ranked #538.

Creekmur Asset Management first reported a position in GANX in Q4 2023 and has held it in 8 quarters since. The position peaked at $16.7K in Q1 2024. 38 funds tracked by Wall St. Rank hold GANX as of Q3 2025.

Creekmur Asset Management held 4,440 shares of Gain Therapeutics worth $7.86K as of Q3 2025.
Creekmur Asset Management left its Gain Therapeutics share count unchanged in Q3 2025.
Gain Therapeutics made up ﹤0.01% of Creekmur Asset Management's portfolio in Q3 2025, its #538 holding.
Creekmur Asset Management first reported a position in Gain Therapeutics in Q4 2023 and has held it in 8 quarters since.
Creekmur Asset Management's Gain Therapeutics position peaked at $16.7K in Q1 2024.
38 funds tracked by Wall St. Rank held Gain Therapeutics as of Q3 2025.

Based on Creekmur Asset Management's 13F filing for Q3 2025, filed 12 Nov 2025.